Effect of patients' risks and preferences on health gains with plasma glucose level lowering in type 2 diabetes mellitus.
about
Polypharmacy in the Aging Patient: A Review of Glycemic Control in Older Adults With Type 2 DiabetesEmerging utility of once-weekly exenatide in patients with type 2 diabetes"Everyone else gets ice cream here more often than I do--It burns me up"--Perspectives on Diabetes Care from Nursing Home Residents and their Doctors.Effects of performance measure implementation on clinical manager and provider motivationAlogliptin benzoate for management of type 2 diabetesIs there evidence of potential overtreatment of glycaemia in elderly people with type 2 diabetes? Data from the GUIDANCE study.Going beyond the disability-based morbidity definition in the compression of morbidity framework.The health system and population health implications of large-scale diabetes screening in India: a microsimulation model of alternative approaches.An Evidence-Based Medicine Approach to Antihyperglycemic Therapy in Diabetes Mellitus to Overcome Overtreatment.Impact of glucose level on morbidity and mortality in elderly with diabetes and pre-diabetesPotential overtreatment of diabetes mellitus in older adults with tight glycemic control.Improving safety of diabetes mellitus management.Prevalence of and Racial Disparities in Risk Factor Control in Older Adults With Diabetes: The Atherosclerosis Risk in Communities StudyDiabetes treatment intensification and associated changes in HbA1c and body mass index: a cohort study.Developing, delivering and evaluating primary mental health care: the co-production of a new complex intervention.Older Adults Reporting More Diabetes Mellitus Care Have Greater 9-Year SurvivalRisk of hypoglycemia following intensification of metformin treatment with insulin versus sulfonylurea.Novel Biomarkers to Improve the Prediction of Cardiovascular Event Risk in Type 2 Diabetes Mellitus.Treated glycosylated hemoglobin levels in individuals with diabetes mellitus vary little by health status: A retrospective cohort study.Impact of statistical models on the prediction of type 2 diabetes using non-targeted metabolomics profiling.Intensive Treatment and Severe Hypoglycemia Among Adults With Type 2 Diabetes.A review of the clinical evidence related to early treatment of elevated LDL for cardiovascular primary prevention.Development and validation of Risk Equations for Complications Of type 2 Diabetes (RECODe) using individual participant data from randomised trials.Is glycemia control in Canadians with diabetes individualized? A cross-sectional observational study.Incretin-Based Therapy for Diabetes: What a Cardiologist Needs to Know.Integrating Biomarkers and Imaging for Cardiovascular Disease Risk Assessment in Diabetes.Comparative effectiveness and cost-effectiveness of treat-to-target versus benefit-based tailored treatment of type 2 diabetes in low-income and middle-income countries: a modelling analysis.Predictors of dual control of HIV and diabetes.Measuring the burden of treatment for chronic disease: implications of a scoping review of the literatureIn pursuit of normoglycaemia: the overtreatment of type 2 diabetes in general practice.The Need for a Tool to Assist Health Care Professionals and Patients in Making Medication Treatment Decisions in the Clinical Management of Type 2 Diabetes.Matching Microsimulation Risk Factor Correlations to Cross-Sectional Data: The Shortest Distance Method.Improved treatment satisfaction and medication adherence after readjusting oral medication regimens with the cooperation of health insurance pharmacy in type 2 diabetic patients in Japan.Individualized Glycemic Control for U.S. Adults With Type 2 Diabetes: A Cost-Effectiveness Analysis.Validation of Risk Equations for Complications of Type 2 Diabetes (RECODe) Using Individual Participant Data From Diverse Longitudinal Cohorts in the U.S.Modelling incremental benefits on complications rates when targeting lower HbA1c levels in people with Type 2 diabetes and cardiovascular disease.When to Start a Statin Is a Preference-Sensitive Decision.Glycemic control in type 2 diabetes: from medication nonadherence to residual vascular risk.Modeling Individual Patient Preferences for Colorectal Cancer Screening Based on Their Tolerance for Complications Risk.Prevention of complications in type 2 diabetes: is drug glucose control evidence based?
P2860
Q26767283-9EB8F33C-8FB4-487D-ACDD-83FDEFC1BE84Q26777320-521EE077-6AEC-4411-97C8-4BEB066E1FC9Q27312839-97BF65C5-B2B7-41EA-A9BE-4D2EDC1F618DQ27312901-16EE7B3C-F2FE-44A0-8D89-DE0A8B67673FQ28083933-E3293511-65EA-4DDC-858E-1B3BE00F7647Q31142015-6E16B605-7C8E-4FA3-B11C-96722AF71122Q34251121-A9069EBB-015B-4370-BEC5-FB33BA587D6DQ34477117-57E670AB-6975-484E-9AF2-593B233B4D7AQ34548875-159043A6-3272-4B80-8641-5C7F9EF215A4Q35179251-9E8FD69A-E784-431B-BCEA-2E49A84B843FQ35592044-4B682D0A-9721-4827-B55C-98B942DF5A26Q35597364-C4A10FD3-3458-4634-812F-AF7AE4B792FFQ35769481-79136E23-46F8-4F3E-A85A-223B33F65A68Q36038607-DD0BFD81-2E93-46BC-BB9B-8A9DE172ED57Q36124493-3701C52E-4225-4812-B6EF-6D852325AFE6Q36396132-6187EB2F-92DA-49E5-B733-C61156F03C27Q36757698-4F440C3C-26B2-41D8-A85B-D2153609D0C1Q37076080-2DA95C3E-FB26-4828-938E-5028EE6BE967Q37205706-71D048E2-D406-42DF-9C66-18077CE78122Q37279013-034D6E8F-5EF6-4804-9E2A-95C07F391597Q37737142-9BFD18CB-0A2C-4E8C-A0A1-46250EDE25ECQ38546910-34659DA0-7C14-4679-8142-21CA866E9265Q38627117-F0FF4E46-CBE7-403D-AEBB-D3FFFF8EB66FQ38650417-7ABE5CC6-F7F4-4F2A-B15C-E370799320FFQ38787756-5E8583F9-ED36-4506-BE8C-57B220195ADCQ38950340-63665D57-F5A0-4C43-A412-EF3D24EFA9D1Q39310857-5051EAA9-87B1-4121-8F2F-B9A9F009AC14Q40352243-A74D72CB-8C8E-470E-85BD-B4C134E6E407Q41172036-BECC4FFF-D3EF-4A8D-83F4-9506EEF22B65Q42389766-F935A538-D8B3-4FC6-8D70-7BFCCACBA80FQ43172161-592B4CC9-92F4-4510-829D-DFE4610F2072Q45940328-22CDCBD8-D16C-46B5-877B-20911F109B87Q47130006-4C8DFFEF-42D2-4136-8200-08F2FEDF0534Q47195337-AD61D62A-A1F5-4670-B0A0-6C3335B1427BQ47263832-801D9884-BA07-417D-A82D-E07E480D725CQ47745744-A4816ECB-8A6F-4E76-8036-26CAB7C5C5B5Q47765690-5C237200-7BDF-44EC-9BFE-F454626A1BF2Q48265337-CD74F938-D3C4-4324-9075-7791BE5AA38EQ48924946-38849186-1133-434F-A2AB-3EC65ED9DA28Q51166971-CAC77224-F886-4DC9-9C9A-7C8B57EEF05B
P2860
Effect of patients' risks and preferences on health gains with plasma glucose level lowering in type 2 diabetes mellitus.
description
2014 nî lūn-bûn
@nan
2014 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Effect of patients' risks and ...... g in type 2 diabetes mellitus.
@ast
Effect of patients' risks and ...... g in type 2 diabetes mellitus.
@en
Effect of patients' risks and ...... g in type 2 diabetes mellitus.
@nl
type
label
Effect of patients' risks and ...... g in type 2 diabetes mellitus.
@ast
Effect of patients' risks and ...... g in type 2 diabetes mellitus.
@en
Effect of patients' risks and ...... g in type 2 diabetes mellitus.
@nl
prefLabel
Effect of patients' risks and ...... g in type 2 diabetes mellitus.
@ast
Effect of patients' risks and ...... g in type 2 diabetes mellitus.
@en
Effect of patients' risks and ...... g in type 2 diabetes mellitus.
@nl
P2093
P2860
P1476
Effect of patients' risks and ...... ng in type 2 diabetes mellitus
@en
P2093
John S Yudkin
Rodney A Hayward
Sandeep Vijan
P2860
P304
P356
10.1001/JAMAINTERNMED.2014.2894
P577
2014-08-01T00:00:00Z